Bonus Biogroup Cash Flow Conversion Efficiency

Latest as of June 2025: 2.402x

Bonus Biogroup cash flow conversion efficiency. Based on the latest financial reports, Bonus Biogroup (BONS) has a cash flow conversion efficiency ratio of 2.402x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-4.02 Million ≈ $-10.79K USD) by net assets (ILA-1.68 Million ≈ $-4.49K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Bonus Biogroup (2008–2025)

Cash flow conversion efficiency of Bonus Biogroup from 2008 to 2025. This chart illustrates how Bonus Biogroup's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bonus Biogroup share price for real-time trading data and today's change.

Bonus Biogroup Cash Flow Conversion Ratio Explained

Bonus Biogroup cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Bonus Biogroup Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bonus Biogroup ranked by their cash flow conversion efficiency. Also see Bonus Biogroup (BONS) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Pangaea Oncology S.A. MC:PANG	-0.057x
Marketwise Inc NASDAQ:MKTW	-0.084x
DDC Enterprise Limited NYSE MKT:DDC	-0.021x
flyExclusive, Inc. NYSE:FLYX	-0.007x
Kuk Dong KO:005320	-0.103x
Oswal Greentech Limited NSE:OSWALGREEN	N/A
Nan Yang Dyeing & Finishing Co Ltd TW:1410	0.002x
Nam Kwang Cons KO:001260	-0.101x

Annual Cash Flow Conversion Efficiency for Bonus Biogroup (2008–2025)

The table below shows the annual cash flow conversion efficiency of Bonus Biogroup from 2008 to 2025. Review how much free cash does Bonus Biogroup generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	ILA-5.66 Million ≈ $-15.18K	ILA-14.93 Million ≈ $-40.03K	2.636x	+185.81%
2024-12-31	ILA6.96 Million ≈ $18.65K	ILA-21.37 Million ≈ $-57.30K	-3.072x	-241.08%
2023-12-31	ILA29.30 Million ≈ $78.57K	ILA-26.40 Million ≈ $-70.77K	-0.901x	-76.27%
2022-12-31	ILA56.39 Million ≈ $151.18K	ILA-28.82 Million ≈ $-77.25K	-0.511x	-8.30%
2021-12-31	ILA84.43 Million ≈ $226.35K	ILA-39.84 Million ≈ $-106.81K	-0.472x	+8.05%
2020-12-31	ILA30.68 Million ≈ $82.26K	ILA-15.75 Million ≈ $-42.21K	-0.513x	-153.70%
2019-12-31	ILA-13.72 Million ≈ $-36.79K	ILA-13.11 Million ≈ $-35.16K	0.956x	-77.39%
2018-12-31	ILA-3.18 Million ≈ $-8.52K	ILA-13.43 Million ≈ $-36.00K	4.226x	+128.21%
2017-12-31	ILA-6.38 Million ≈ $-17.12K	ILA-11.82 Million ≈ $-31.70K	1.852x	+41.67%
2016-12-31	ILA-7.36 Million ≈ $-19.74K	ILA-9.62 Million ≈ $-25.80K	1.307x	-77.50%
2015-12-31	ILA-1.39 Million ≈ $-3.72K	ILA-8.07 Million ≈ $-21.63K	5.809x	+144.38%
2014-12-31	ILA604.00K ≈ $1.62K	ILA-7.91 Million ≈ $-21.20K	-13.091x	-1005.65%
2013-12-31	ILA6.45 Million ≈ $17.28K	ILA-7.63 Million ≈ $-20.46K	-1.184x	+8.53%
2012-12-31	ILA7.47 Million ≈ $20.03K	ILA-9.67 Million ≈ $-25.93K	-1.294x	-132.19%
2011-12-31	ILA-881.00K ≈ $-2.36K	ILA-3.54 Million ≈ $-9.50K	4.022x	+7812.81%
2010-12-31	ILA-38.19 Million ≈ $-102.39K	ILA-1.94 Million ≈ $-5.20K	0.051x	-63.07%
2009-12-31	ILA-9.38 Million ≈ $-25.15K	ILA-1.29 Million ≈ $-3.46K	0.138x	-92.04%
2008-12-31	ILA11.86 Million ≈ $31.81K	ILA20.52 Million ≈ $55.01K	1.730x	--

About Bonus Biogroup

TA:BONS Israel Biotechnology

Market Cap

$51.35 Million

ILA19.15 Billion ILA

Market Cap Rank

#21613 Global

#288 in Israel

Share Price

ILA16.40

Change (1 day)

+1.23%

52-Week Range

ILA16.20 - ILA58.50

All Time High

ILA171.00